--------------------------------------------------------------------------------

CONFIDENTIAL TREATMENT REQUESTED
UNDER 17 C.F.R §§ 200.80(B)4, AND 240.24B-2

 
Exhibit 10.61
 
Execution Copy

AMENDMENT NO.2
 
This Amendment No.2 (“the “Amendment”) to the Collaboration, License and
Development Agreement dated December 7th, 2012 (the “Agreement”), is made by and
between

(1)
ASTRAZENECA AB, a company incorporated in Sweden under no. 556011-7482 with its
registered office at 151 85 Södertälje, Sweden and with offices at SE-43 183
Mölndal, Sweden (“AstraZeneca”)

(2)
Isis Pharmaceuticals, Inc., a Delaware corporation, having its principal place
of business at 2855 Gazelle Court, Carlsbad, CA 92010 (“Isis”)

and is made effective as of the 15th day of October, 2014 (the “Amendment
Effective Date”)

Recitals

WHEREAS, the Parties desire to further amend, modify and restate certain terms
and conditions of the Agreement.

Agreement

     NOW, THEREFORE, in consideration of the mutual covenants contained in this
Amendment, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties, intending to be
legally bound, agree as follows:

1.
Definitions

Any capitalized term not separately defined in this Amendment shall have the
meaning ascribed to it in the Agreement.

2.
Modifications

Article 8.4, Table 1, shall be deleted and replaced by the following:
 

Table 1  
STAT3 Product Milestone Event
 
Column 1
STAT3 Product Milestone Event Payment for High Response Outcome
   
Column 2
STAT3 Product Milestone Event Payment for Medium Response Outcome or Low
Response Outcome
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 
[***]
 
$
[***]
   
$
[***]
 

 

--------------------------------------------------------------------------------

3.
Amendment Effective Date

This Amendment shall become effective on the Amendment Effective Date.

4.
Entire Agreement

This Amendment, together with the Agreement, constitutes the entire agreement
between the Parties with respect to the subject matter of the Agreeement. The
Agreeemnt together with this Amendment and any prior Amendments thereto
supersedes all prior agreements, whether written or oral, with respect to the
subject matter of the Agreeemnet, as amended. Each Party confirms that it is not
relying on any representations, warranties or covenants of the other Party
except as specifically set out in the Agreement as amended. Nothing in this
Agreement is intended to limit or exclude any liability or fraud. All Schedules
referred to in this Amendment are intended to be and are hereby specifically
incorporated into and made a part of the Agreement. The Parties hereby agree
that subject to the modifciations specifically stated in this Amendment, all
other terms and conditions of the Agreement shall remain in full force and
effect.

Execution
THIS AGREEMENT IS EXECUTED by the authorized representatives of the parties as
of the date first written above.

ASTRAZENECA AB
 
ISIS Pharmaceuticals, INC
 
Signature : 
/s/ M. Schindler
 
Signature : 
/s/ B. Lynne Parshall
 
Name :
M. Schindler
 
Name :
B. Lynne Parshall
 
Title :
16 10 14
 
Title :
Chief Operating Officer

 

--------------------------------------------------------------------------------